drugset / Trial / NCT02052661

This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa

NCT02052661 ↗

Phase 4 Completed 301 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 12-13 years who were vaccinated with four doses of Infanrix™-Hexa in infancy and to assess the anamnestic response, immunogenicity, safety and reactogenicity of a single challenge dose of the hepatitis B vaccine Engerix™-B Kinder.

Timeline

Start
2014-02-18
Primary completion
2014-09-23
Completion
2014-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Engerix™-B Kinder Vaccine — Intramuscular